# Recombinant Human Hyaluronidase in Treating Lymphedema in Patients With Cancer

> **NCT01928030** · PHASE1,PHASE2 · TERMINATED · sponsor: **Stanford University** · enrollment: 3 (actual)

## Conditions studied

- Lymphedema
- Malignant Neoplasm

## Interventions

- **BIOLOGICAL:** recombinant human hyaluronidase

## Key facts

- **NCT ID:** NCT01928030
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-12
- **Primary completion:** 2015-11
- **Final completion:** 2015-11
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Low accrual
- **Last updated:** 2017-03-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01928030

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01928030, "Recombinant Human Hyaluronidase in Treating Lymphedema in Patients With Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01928030. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*